Abstract
Macrocyclic lactones (MLs), exemplified by the prototype of the class, ivermectin (IVM), are mainstays of programs for the control of nematode and arthropod parasites and pests. Since their introduction 30 years ago, research has revealed that they act on a family of ligand-gated chloride channels gated by glutamate, which is largely restricted to animals in the phyla Nematoda and Arthropoda. Studies on IVM in model organisms have contributed greatly to our understanding of ML pharmacology, but our understanding of the basis for differences among species and among MLs in potency and spectrum remains far from complete.
Keywords: Nematode, parasite, arthropod, glutamate-gated chloride channel, ivermectin
Current Pharmaceutical Biotechnology
Title:Macrocyclic Lactone Anthelmintics: Spectrum of Activity and Mechanism of Action
Volume: 13 Issue: 6
Author(s): Timothy G. Geary and Yovany Moreno
Affiliation:
Keywords: Nematode, parasite, arthropod, glutamate-gated chloride channel, ivermectin
Abstract: Macrocyclic lactones (MLs), exemplified by the prototype of the class, ivermectin (IVM), are mainstays of programs for the control of nematode and arthropod parasites and pests. Since their introduction 30 years ago, research has revealed that they act on a family of ligand-gated chloride channels gated by glutamate, which is largely restricted to animals in the phyla Nematoda and Arthropoda. Studies on IVM in model organisms have contributed greatly to our understanding of ML pharmacology, but our understanding of the basis for differences among species and among MLs in potency and spectrum remains far from complete.
Export Options
About this article
Cite this article as:
G. Geary Timothy and Moreno Yovany, Macrocyclic Lactone Anthelmintics: Spectrum of Activity and Mechanism of Action, Current Pharmaceutical Biotechnology 2012; 13 (6) . https://dx.doi.org/10.2174/138920112800399077
DOI https://dx.doi.org/10.2174/138920112800399077 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Challenges in Neuronal Apoptosis
Current Alzheimer Research Targeting Ras-RAF-ERK and its Interactive Pathways as a Novel Therapy for Malignant Gliomas
Current Cancer Drug Targets Botulinum Toxin as a Neuro-Relearning Drug Tool in Motor Paralytic Disorders
Current Drug Therapy RNA Interference (RNAi) Patents and Human Health Related Applications of RNAi
Recent Patents on DNA & Gene Sequences Lithium Restores Age-related Olfactory Impairment in the Ts65Dn Mouse Model of Down Syndrome
CNS & Neurological Disorders - Drug Targets Metabolic Reprogramming of Human Cells in Response to Oxidative Stress: Implications in the Pathophysiology and Therapy of Mitochondrial Diseases
Current Pharmaceutical Design Pathogenesis of Stroke-Like Episodes in MELAS: Analysis of Neurovascular Cellular Mechanisms
Current Neurovascular Research Genomic and Epigenetic Complexity of the FOXF1 Locus in 16q24.1: Implications for Development and Disease
Current Genomics Glial Cells – The Key Elements of Alzheimer´s Disease
Current Alzheimer Research Transcranial Magnetic Stimulation of Degenerating Brain: A Comparison of Normal Aging, Alzheimer’s, Parkinson’s and Huntington's Disease
Current Alzheimer Research Combined Therapies for Lysosomal Storage Diseases
Current Molecular Medicine Catatonia, Malignant Catatonia, and Neuroleptic Malignant Syndrome
Current Psychiatry Reviews Potential Roles of HDAC Inhibitors in Mitigating Ischemia-induced Brain Damage and Facilitating Endogenous Regeneration and Recovery
Current Pharmaceutical Design Properties and Pathogenicity of Prion-Derived Peptides
Protein & Peptide Letters Therapeutic Options in Prevention and Treatment of Aspartoacylase Gene Mutation Resulting Abnormalities in Canavan Disease
Current Pharmacogenomics Brain Structural Substrates of Semantic Memory Decline in Mild Cognitive Impairment
Current Alzheimer Research Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction
Current Topics in Medicinal Chemistry Old Strategies and New Perspectives in Modulating the Endocannabinoid System
Current Bioactive Compounds Pharmacological Studies of Smooth Pursuit and Antisaccade Eye Movements in Schizophrenia: Current Status and Directions for Future Research
Current Neuropharmacology Abnormal Striatal Dopamine Transmission in Schizophrenia
Current Medicinal Chemistry